Femtech and Period-Tracking Apps: Who Controls Your Data?

I tapped "confirm period" on my phone at 7:15 a.m. and watched the app log day one of my cycle before I even brushed my teeth. The notification thanked me for helping it learn my patterns. I was twenty and living in a dorm room in Austin, surrounded by three other women who used similar apps, and none of us had read a single privacy policy. We traded screenshots comparing our mood predictions and ovulation windows like weather forecasts. It felt intimate and scientific at once, a private ritual made shareable.

Only later, during a women's studies seminar my junior year, did I learn that this data I created each month was being stored, analyzed, and sometimes sold to third parties I had never heard of. The question of who controls menstrual health data has become urgent as these apps gain users, and the answer reveals how easily personal biology becomes a commodity when technology companies mediate our most private experiences.

Period-tracking apps, part of the larger femtech industry, allow users to log menstrual cycles, symptoms, sexual activity, and fertility indicators. Companies like Flo, Clue, and Ovia market these tools as empowering, giving women insight into their bodies that previous generations lacked. The femtech sector has grown rapidly since 2015, driven by venture capital investment and the widespread adoption of smartphones. These apps promise personalized health predictions using algorithms that learn from user input. However, the data women enter is not simply stored on their devices. It often travels to company servers, where it may be shared with advertisers, data brokers, or research partners. The regulatory environment around health data is inconsistent, leaving gaps that companies exploit. Understanding who accesses this information requires examining both the technology itself and the legal structures that govern it.

When I first downloaded my tracking app during freshman orientation, I answered questions about my cycle length, birth control use, and whether I was trying to conceive. The interface felt like a journal, private and mine. I did not realize that my answers were feeding a database accessible to the company's employees and potentially its partners. A year later, I started noticing ads for fertility supplements and pregnancy tests on my social media feeds, even though I had never searched for them. The targeting felt invasive, like someone had read my diary. I learned that many apps share anonymized data with third parties, but anonymization is often incomplete. Researchers have shown that combining a few data points, like zip code and age, can re-identify individuals. My cycle data, merged with my location history or browsing habits, could paint a detailed portrait of my health and intentions. The app's terms of service mentioned data sharing in vague language buried in paragraphs I never read, and I doubt I was alone in that oversight.

The legal protections for menstrual health data vary by country and state, creating a patchwork of rules that companies navigate strategically. In the United States, the Health Insurance Portability and Accountability Act covers data held by healthcare providers, but most femtech apps do not qualify as covered entities. This means the strict privacy rules that protect medical records do not apply to apps women use daily. Some states have enacted consumer privacy laws that give users limited control, like the right to request deletion, but enforcement is weak. In Europe, the General Data Protection Regulation offers stronger protections, requiring explicit consent and limiting data transfers. Yet even under these rules, companies find ways to justify data sharing as necessary for app functionality. After the Supreme Court overturned constitutional abortion protections in 2022, concerns intensified that period data could be used to prosecute women or identify pregnancies. Law enforcement can subpoena app companies for user records, and unless the company refuses or users delete their data, menstrual logs become potential evidence.

Beyond legal risks, the concentration of menstrual data in private hands raises questions about who benefits from this information. Pharmaceutical companies and researchers pay for access to aggregated data, using it to study fertility trends or test new products. While this can advance medical knowledge, the women generating the data rarely share in the financial gains or influence how their information is used. I remember a guest speaker in my public health class explaining that marginalized communities, including low-income women and women of color, are often excluded from the app development process, yet their data is still harvested if they use free versions. These apps may reinforce existing health disparities by tailoring features to wealthier users who can afford premium subscriptions while mining data from everyone. The asymmetry troubles me because it treats women's bodies as resources rather than as belonging fully to the individuals who live in them.

I still use a period-tracking app, but I changed how I interact with it after spending a semester researching data privacy. I switched to an app that stores data locally on my device rather than in the cloud, and I stopped logging details beyond the basics. I miss the detailed insights my old app provided, the sense of understanding my body's rhythms, but I value the control more. The convenience of these tools is real, and I do not think women should abandon them entirely. Instead, we need stronger regulations that treat menstrual data as sensitive health information deserving the same protections as medical records. Companies should be required to disclose data practices in plain language, obtain informed consent, and allow users to own and delete their information completely. As femtech continues to grow, the challenge is ensuring that technology serves women's autonomy rather than turning our biology into a profit stream that others control without our full awareness or agreement.

Did you like this example?

280

12